Scholarlink

Background <p>Aberrant phase separation (PS) has emerged as a pivotal pathogenic mechanism in cancer development. However, its prognostic significance and influence on the tumor immune microenvironment in gastric cancer (GC) remain largely unexplored. This study aimed to develop a PS-related risk model for predicting clinical outcomes and immunotherapy response, and to identify potential natural small-molecule compounds targeting proteins within this PS-related network.</p> Methods <p>We integrated transcriptomic data from the TCGA-STAD and GSE62254 datasets with four PS-related databases (including DrLLPS, PhaSepDB, PhaSePro, and LLPSDB) to identify candidate signature genes. The prognostic model was developed using least absolute shrinkage and selection operator (LASSO) regression and validated in both cohorts. Immune checkpoint inhibitor (ICI) response between PS-related high- and low-risk groups was evaluated using TIDE algorithm scores. Potential therapeutic agents targeting signature genes were screened via Connectivity Map and HERB database analyses, followed by molecular docking validation.</p> Results <p>By Integrating analysis of the differential expression dataset from TCGA-STAD (<i>n</i> = 407, 375 tumor/32 normal) with prognosis-related dataset and PS-related dataset, we identified 78 candidate genes and developed a robust 21-gene risk prediction model. The model effectively stratified GC patients into high-risk and low-risk subgroups, with consistent performance in the independent GSE62254 validation cohort (<i>n</i> = 300, tumor). Compared to low-risk patients, high-risk patients exhibited poorer survival, a more immunosuppressive microenvironment, and a reduced response to immunotherapy. Moreover, computational screening identified 18 potential therapeutic natural compounds, 13 of which showed high-affinity binding to signature genes (docking scores &gt; 6.0).</p> Conclusions <p>Our study developed a novel PS-related risk model that predicts GC outcomes, characterizes tumor immune microenvironment, evaluates immunotherapy response, and identifies targeting small molecules. These findings advance the understanding of PS regulation in GC and provide a framework for personalized therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A phase separation-related gene signature for prognosis prediction and immunotherapy response evaluation in gastric cancer with targeted natural compound discovery

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月23日

查看全文
  • Yanjuan Jia,
  • Yuanyuan Ma,
  • Zhenhao Li,
  • Wenze Zhang,
  • Rukun Lu,
  • Wanxia Wang,
  • Chaojun Wei,
  • Chunyan Wei,
  • Yonghong Li,
  • Xiaoling Gao,
  • Tao Qu

摘要

Background

Aberrant phase separation (PS) has emerged as a pivotal pathogenic mechanism in cancer development. However, its prognostic significance and influence on the tumor immune microenvironment in gastric cancer (GC) remain largely unexplored. This study aimed to develop a PS-related risk model for predicting clinical outcomes and immunotherapy response, and to identify potential natural small-molecule compounds targeting proteins within this PS-related network.

Methods

We integrated transcriptomic data from the TCGA-STAD and GSE62254 datasets with four PS-related databases (including DrLLPS, PhaSepDB, PhaSePro, and LLPSDB) to identify candidate signature genes. The prognostic model was developed using least absolute shrinkage and selection operator (LASSO) regression and validated in both cohorts. Immune checkpoint inhibitor (ICI) response between PS-related high- and low-risk groups was evaluated using TIDE algorithm scores. Potential therapeutic agents targeting signature genes were screened via Connectivity Map and HERB database analyses, followed by molecular docking validation.

Results

By Integrating analysis of the differential expression dataset from TCGA-STAD (n = 407, 375 tumor/32 normal) with prognosis-related dataset and PS-related dataset, we identified 78 candidate genes and developed a robust 21-gene risk prediction model. The model effectively stratified GC patients into high-risk and low-risk subgroups, with consistent performance in the independent GSE62254 validation cohort (n = 300, tumor). Compared to low-risk patients, high-risk patients exhibited poorer survival, a more immunosuppressive microenvironment, and a reduced response to immunotherapy. Moreover, computational screening identified 18 potential therapeutic natural compounds, 13 of which showed high-affinity binding to signature genes (docking scores > 6.0).

Conclusions

Our study developed a novel PS-related risk model that predicts GC outcomes, characterizes tumor immune microenvironment, evaluates immunotherapy response, and identifies targeting small molecules. These findings advance the understanding of PS regulation in GC and provide a framework for personalized therapy.